UGISense Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series B

  • Investors
  • 2

UGISense General Information

Description

Developer of a biotechnology platform designed to develop antisense drugs for genetic and acquired conditions. The company offers a platform featuring highly stable, specific, and effective Ugimers molecules with customizable chemical modifications, enabling pharmaceutical partners to develop and improve therapies for diseases.

Contact Information

Formerly Known As
Blitz 16-572 AG
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Otto-Hahn-Straße 15
  • 44227 Dortmund
  • Germany
+49 0231
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Otto-Hahn-Straße 15
  • 44227 Dortmund
  • Germany
+49 0231

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

UGISense Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 29-Apr-2021 Completed Generating Revenue
2. Early Stage VC (Series A) 24-May-2018 Completed Generating Revenue
1. Corporate 12-Oct-2016 $1.34M $1.34M Completed Generating Revenue
To view UGISense’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

UGISense Patents

UGISense Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2683186-T3 Monomers and oligomers of peptidonucleic acid Active 16-May-2014
AU-2015258476-A1 Peptide nucleic acid monomers and oligomers Active 16-May-2014
AU-2015258476-B2 Peptide nucleic acid monomers and oligomers Active 16-May-2014
CA-2949185-A1 Peptide nucleic acid monomers and oligomers Active 16-May-2014
CA-2949185-C Peptide nucleic acid monomers and oligomers Active 16-May-2014 C07D473/18
To view UGISense’s complete patent history, request access »

UGISense Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

UGISense Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Sparkasse Dortmund Venture Capital Minority
Lead Discovery Center Corporation Minority
To view UGISense’s complete investors history, request access »

UGISense FAQs

  • When was UGISense founded?

    UGISense was founded in 2016.

  • Where is UGISense headquartered?

    UGISense is headquartered in Dortmund, Germany.

  • What is the size of UGISense?

    UGISense has 6 total employees.

  • What industry is UGISense in?

    UGISense’s primary industry is Drug Discovery.

  • Is UGISense a private or public company?

    UGISense is a Private company.

  • What is UGISense’s current revenue?

    The current revenue for UGISense is .

  • How much funding has UGISense raised over time?

    UGISense has raised $1.34M.

  • Who are UGISense’s investors?

    Sparkasse Dortmund and Lead Discovery Center have invested in UGISense.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process